* Singular Genomics Systems Inc OMIC.OQ reported a
quarterly
adjusted loss of $8.57 per share for the quarter ended in
June, higher than the same quarter last year, when the company
reported EPS of $-10.50. The mean expectation of two analysts
for the quarter was for a loss of $8.86 per share. Wall Street
expected results to range from $-8.95 to $-8.77 per share.
* Revenue rose 45.9% to $737.00 thousand from a year ago;
analysts
expected $400.00 thousand.
* Singular Genomics Systems Inc's reported EPS for the
quarter was
a loss of $8.57.
* The company reported a quarterly loss of $21.25 million.
* Singular Genomics Systems Inc shares had fallen by 15.7%
this
quarter and lost 48.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 0.1%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Singular Genomics
Systems Inc is $6.50
This summary was machine generated from LSEG data August 13 at
09:57 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -8.86 -8.57 Beat
Mar. 31 2024 -10.50 -10.20 Beat
Dec. 31 2023 -10.30 -9.60 Beat
Sep. 30 2023 -11.40 -9.30 Beat